Latest Headlines

Latest Headlines

PhIII failure dashes Novartis' hopes of Gilenya label expansion

Novartis is looking to expand sales of oral multiple sclerosis therapy Gilenya, which currently trails Biogen Idec pill Tecfidera in the MS arena despite its first-to-market advantage. But it looks like it won't be doing that with a primary progressive MS indication anytime soon.

Novartis MS drug Gilenya could relieve painful side effect of chemo

Novartis' multiple sclerosis drug Gilenya may be able to mitigate a painful side effect of chemotherapy in cancer patients, according to a new preclinical study.

Novartis MS drug prevents heart failure in animal study

Scientists believe a drug approved to treat multiple sclerosis may also be able to help prevent an unrelated medical condition--heart failure.

Novartis MS drug could help beat bowel cancer

Novartis' multiple sclerosis drug Gilenya (fingolimod) could treat or even prevent colitis-associated cancer, if preclinical findings from U.S. researchers can be confirmed in later studies.

Novartis leans on emerging markets, new meds to offset Diovan drop

Novartis is gaining in emerging markets. It's also seeing growth in newly launched products, including a few potential blockbusters. Both very good things--and sorely needed to offset a manufacturing shutdown and eroding sales of its top-selling drug.

SRI gets Defense grant to develop oral-delivered MS drug

The Department of Defense has awarded a one-year grant to SRI International's bioscience division to develop an orally administered multiple sclerosis drug.

UPDATED: EMA approves Novartis' Gilenya

The drug dodged a bullet in the EU when the European Medicines Agency said it could remain on the market.

Novartis reports patient taking Gilenya developed rare brain disease

Expectations for the blockbuster status of Gilenya dimmed when Novartis disclosed that a patient taking the drug has developed a rare brain disease.

Watchdog says FDA should consider restricting Gilenya

The Institute for Safe Medicine Practices has zeroed in on Novartis' new multiple sclerosis pill.

Novartis persuades NICE to endorse Gilenya

The U.K.'s cost-effectiveness watchdog has changed its mind about Gilenya. The National Institute for Health and Clinical Excellence at first rejected the Novartis multiple sclerosis pill, in spite of an up-front discount offer. Now, thanks to some new data from the Swiss drugmaker, NICE has decided to recommend the drug instead.